The Cost-Effectiveness of GaitSmart Rehabilitation Programme

By Staff Writer

April 4, 2024

Understanding GaitSmart Rehabilitation Programme

GaitSmart, a rehabilitation exercise initiative, is designed to address mobility and gait issues. This CE marked class 1 medical device uses sensor-based digital technology. It monitors limb movement and assesses gait, creating a colour-coded report for patients and healthcare professionals. The test takes about 10 minutes and is usable in various settings. This fully automated, innovative technology seeks to improve gait assessment. It also aims to increase access to objective gait analysis, which could improve patient outcomes. In this article we highlight some aspects provided by The National Institute for Health and Care Excellence (NICE) in their recent review of the GaitSmart Rehabilitation Programme and its cost-effectiveness.

Clinical Effectiveness of GaitSmart

The clinical effectiveness of GaitSmart is a crucial factor in its overall value proposition. The technology has shown promising results in improving gait assessment and the choice of intervention, which could lead to improved patient outcomes. The clinical experts have noted that the risk of falls calculated by the external assessment group (EAG) was more realistic than that included in the company’s models. However, the experts have also pointed out the need for more evidence on GaitSmart’s clinical effectiveness, particularly in people at risk of falls. Ongoing and planned pilots evaluating GaitSmart’s use in the National Health Service (NHS) are expected to provide this much-needed evidence.

Cost Analysis of GaitSmart

The GaitSmart program costs about £82.00 per user. This price includes four assessment sessions and the vGym rehabilitation exercise program. It also covers the cost of hiring a healthcare assistant. The cost-saving potential of GaitSmart is significant when compared to standard care, primarily due to the reduced need for healthcare professional time and resources.

Cost Modelling and Savings

The company’s cost model revealed a cost saving of £2.90 per person using GaitSmart for fall risk, and £450.56 per person for hip and knee rehabilitation. The EAG revised these figures. They showed that GaitSmart saves £80.39 compared to standard care for hip or knee replacements. They also showed a saving of £28.70 for people at risk of falls compared to individual physiotherapy. 

Further Evidence and Research

While the current evidence strongly suggests the cost-effectiveness of GaitSmart, further research is needed to solidify these findings. Several ongoing pilots evaluating GaitSmart’s use in the NHS could address existing uncertainties and provide more robust evidence of its benefits.

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.